Co esponding au ho : Bandela Abhilash
Copy igh © 2025 Au ho (s) e ain he copy igh o his a icle. This a icle is published unde he e ms o he C ea i e Commons A ibu ion License 4.0.
No el bioma ke s in ea ly disease de ec ion
Bandela Abhilash 1, *, Ye ikala Ramesh 2, Venugopalaiah Penabaka 2 and Yadala P apu na Chand a 3
1 IV Yea B.Pha macy, Ra nam Ins i u e o Pha macy, Pida hapolu (V &P), SPSR Nello e – 524 346.
2 Depa men o Pha maceu ics, Ra nam Ins i u e o Pha macy, Pida hapolu (V &P), SPSR Nello e – 524 346.
3 Depa men o Pha macology, Ra nam Ins i u e o Pha macy, Pida hapolu (V &P), SPSR Nello e – 524 346.
Bandela Abhilash : h ps://o cid.o g/0009-0009-8598-5681
Ye ikala Ramesh : h ps://o cid.o g/0000-0002-8331-8190
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
Publica ion his o y: Recei ed on 20 Sep embe 2025; e ised on 28 Oc obe 2025; accep ed on 31 Oc obe 2025
A icle DOI: h ps://doi.o g/10.30574/gscbps.2025.33.1.0418
Abs ac
De ec ing diseases a an ea ly s age is c ucial o imp o ing su i al a es, ensu ing imely ea men , and minimizing
heal hca e bu dens. T adi ional diagnos ic echniques, such as imaging and biochemical es ing, o en iden i y diseases
only a e symp oms become e iden , which educes hei e ec i eness in ea ly diagnosis. In con as , no el bioma ke s
ha e eme ged as p omising ools ha enable de ec ion o pa hological al e a ions a he molecula and cellula le el
long be o e clinical signs appea .
Bioma ke s se e as quan i iable indica o s o physiological o pa hological p ocesses and he apeu ic esponses.
Ad ances in molecula biology, genomics, p o eomics, and me abolomics ha e expanded he disco e y o no el
bioma ke s, including ci cula ing umo DNA (c DNA), mic oRNAs, exosomes, and speci ic me abolic pa e ns. These
inno a i e indica o s show g ea po en ial o he ea ly iden i ica ion o cance s, ca dio ascula condi ions,
neu odegene a i e diseases, and in ec ious diso de s.
Beyond ea ly de ec ion, no el bioma ke s assis in disease isk e alua ion, p ognosis, and moni o ing o ea men
e icacy. Thei g owing use aligns wi h he p inciples o pe sonalized and p ecision medicine, enabling ailo ed
diagnos ic and he apeu ic s a egies o indi idual pa ien s.
Ne e heless, he implemen a ion o hese bioma ke s in clinical se ings aces challenges, such as lack o alida ion,
s anda diza ion issues, and egula o y cons ain s. Ongoing esea ch and echnological p og ess a e essen ial o
o e come hese ba ie s and ully ealize he po en ial o no el bioma ke s in ans o ming ea ly disease de ec ion and
enhancing global heal h ou comes.
Keywo ds: No el Bioma ke s; Ea ly Diagnosis; Molecula De ec ion; P ecision Medicine; Disease P ognosis
1. In oduc ion
Ea ly disease de ec ion is a co ne s one o e ec i e heal hca e, as imely diagnosis signi ican ly imp o es ea men
ou comes, educes mo bidi y, and lowe s heal hca e cos s. T adi ional diagnos ic me hods, such as imaging,
his opa hological examina ion, and biochemical assays, hough aluable, o en de ec diseases only a e clinical
symp oms appea . This delay can limi ea men op ions and dec ease su i al a es, pa icula ly in condi ions like
cance , ca dio ascula disease, and neu odegene a i e diso de s. Hence, he e is a g owing need o ad anced
diagnos ic ools ha can iden i y diseases a hei ea lies molecula o cellula s ages.1
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
365
Bioma ke smeasu able biological indica o s o no mal o pa hological p ocessesha e eme ged as powe ul ools in his
con ex . They can be de i ed om a a ie y o biological sou ces, including blood, u ine, issues, and o he body luids.
Con en ional bioma ke s, while use ul, o en lack sensi i i y o speci ici y o ea ly-s age disease de ec ion. Recen
ad ancemen s in molecula biology, genomics, p o eomics, and me abolomics ha e led o he disco e y o no el
bioma ke s ha o e g ea e p ecision, enabling he iden i ica ion o disease-associa ed changes long be o e clinical
mani es a ions occu 2.
These no el bioma ke s no only enhance ea ly diagnosis bu also aid in isk assessmen , disease classi ica ion, and
moni o ing he apeu ic esponses. Fo ins ance, ci cula ing umo DNA (c DNA), mic oRNAs, and exosomes ha e shown
emendous po en ial in de ec ing cance s a subclinical s ages. Simila ly, p o ein-based and me abolic bioma ke s a e
p o iding new insigh s in o neu odegene a i e and me abolic diso de s3.
The in eg a ion o no el bioma ke s in o diagnos ic p ac ice ma ks a shi owa d pe sonalized and p edic i e medicine,
whe e in e en ions can be ailo ed o an indi idual’s unique molecula p o ile. As esea ch p og esses, he con inued
de elopmen and alida ion o no el bioma ke s hold he p omise o ans o ming ea ly disease de ec ion, ul ima ely
imp o ing pa ien p ognosis and ad ancing p ecision heal hca e4.
1.1. Impo ance o Ea ly Disease De ec ion
Ea ly disease de ec ion plays a i al ole in imp o ing clinical ou comes and enhancing he e ec i eness o heal hca e
sys ems. De ec ing diseases a hei ini ial s ages allows o imely in e en ion, which can signi ican ly educe
mo bidi y, mo ali y, and o e all ea men cos s. In condi ions such as cance , ca dio ascula disease, and
neu odegene a i e diso de s, ea ly diagnosis o en de e mines he success o he apy and long- e m su i al a es.
T adi ional diagnos ic app oaches, including imaging and his opa hological examina ions, gene ally iden i y diseases
only a e symp oms become e iden o when subs an ial issue damage has occu ed. This delay in de ec ion limi s
he apeu ic op ions and educes he likelihood o achie ing comple e emission. Con e sely, iden i ying molecula and
cellula al e a ions be o e clinical mani es a ion enables he implemen a ion o p e en i e o a ge ed he apeu ic
s a egies5.
Ad ancemen s in molecula biology, genomics, and bioin o ma ics ha e enabled he de elopmen o sensi i e diagnos ic
ools capable o iden i ying subclinical disease ma ke s. These inno a ions a e pa ing he way o p edic i e and
pe sonalized medicine, allowing heal hca e p o essionals o s a i y pa ien isk, ailo ea men s, and moni o disease
p og ession mo e e ec i ely.
Ul ima ely, ea ly disease de ec ion no only imp o es pa ien p ognosis bu also educes he socioeconomic bu den o
ch onic diseases by minimizing he need o ex ensi e and cos ly la e-s age ea men s 6.
1.2. Limi a ions o Con en ional Diagnos ic Me hods
Con en ional diagnos ic echniquessuch as imaging, biochemical assays, and his opa hological examina ions—ha e
long se ed as essen ial ools in medical p ac ice. While hese app oaches emain cen al o disease diagnosis, hey
possess se e al limi a ions ha es ic hei e ec i eness in de ec ing diseases a ea ly s ages.
A p ima y limi a ion is hei inabili y o iden i y molecula changes p eceding clinical symp oms. Many diseases,
including cance and neu odegene a i e diso de s, unde go leng hy asymp oma ic phases du ing which cellula and
molecula al e a ions occu . T adi ional diagnos ic ools ypically de ec abno mali ies only once s uc u al o
unc ional damage is al eady signi ican , he eby delaying in e en ion7.
Ano he limi a ion lies in hei es ic ed sensi i i y and speci ici y. Imaging me hods such as X- ays, CT scans, and MRI
can e eal ana omical abno mali ies bu may ail o dis inguish be ween benign and malignan o ea ly-s age lesions.
Simila ly, biochemical assays o en measu e nonspeci ic ma ke s in luenced by mul iple physiological a iables, which
can lead o alse-posi i e o alse-nega i e esul s8.
Fu he mo e, his opa hological examina ions, al hough conside ed he diagnos ic gold s anda d o many diseases, a e
in asi e and ime-consuming. They depend hea ily on issue a ailabili y and pa hologis in e p e a ion, leading o
po en ial subjec i i y and in e -obse e a iabili y. These limi a ions no only delay diagnosis bu also con ibu e o
diagnos ic e o s and inc eased heal hca e cos s.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
366
Addi ionally, con en ional diagnos ics o en lack p edic i e capabili y, o e ing limi ed insigh in o disease p og ession
o he apeu ic esponse. In con as , eme ging molecula and genomic echnologies p o ide oppo uni ies o ea lie ,
mo e accu a e, and pe sonalized de ec ion by iden i ying bioma ke s ha e lec disease ac i i y a he molecula le el9.
Figu e 1 Bioma ke Ca ego ies and Domain
2. Bioma ke s – an o e iew
2.1. De ini ion and Types o Bioma ke s
A bioma ke (biological ma ke ) is a measu able indica o o no mal biological p ocesses, pa hogenic p ocesses, o
pha macological esponses o he apeu ic in e en ions. Bioma ke s can be molecules, genes, p o eins, me aboli es, o
e en imaging indings ha objec i ely e lec physiological o disease s a es.10
Acco ding o he U.S. Na ional Ins i u es o Heal h (NIH), bioma ke s a e classi ied in o se e al ypes based on hei
unc ion
• Diagnos ic bioma ke s iden i y he p esence o a disease o condi ion.
• P ognos ic bioma ke s gi e de ails abou how a condi ion is expec ed o p og ess o u n ou .
• The possibili y o a esponse o a pa icula ea men is indica ed by p edic i e bioma ke s.
• Pha macodynamic o esponse bioma ke s measu e he biological esponse o a he apy.
• Moni o ing bioma ke s a e used o assess he s a us o a disease o ea men o e ime.
Recen ad ances in genomics, p o eomics, and me abolomics ha e expanded bioma ke esea ch, leading o he
disco e y o no el molecula bioma ke s wi h high sensi i i y and speci ici y o ea ly disease de ec ion11.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
367
2.2. Role o Bioma ke s in Clinical P ac ice
Bioma ke s play a pi o al ole in mode n clinical medicine, suppo ing diagnosis, p ognosis, disease moni o ing, and
pe sonalized ea men s a egies. In oncology, o example, bioma ke s such as HER2 in b eas cance and EGFR
mu a ions in lung cance help ailo a ge ed he apies, imp o ing pa ien ou comes12.
In ca dio ascula disease, ca diac oponins se e as gold-s anda d bioma ke s o ea ly de ec ion o myoca dial
in a c ion. Simila ly, bioma ke s like amyloid-β and au p o eins a e c i ical in diagnosing neu odegene a i e diseases
such as Alzheime ’s disease.
Beyond diagnosis, bioma ke s guide d ug de elopmen and clinical ials by p edic ing he apeu ic e icacy and oxici y,
hus educing he ime and cos o d ug disco e y. The in eg a ion o bioma ke -based diagnos ics in o clinical
wo k lows ep esen s a key componen o p ecision and pe sonalized medicine, allowing ea men s o be cus omized
o indi idual biological p o iles 13.
3. No el Bioma ke s in Ea ly Disease De ec ion
Ea ly disease de ec ion is essen ial o imp o ing clinical ou comes, enabling p e en i e in e en ions, and educing
heal hca e cos s. Con en ional diagnos ic me hods o en ail o iden i y diseases in hei p eclinical s ages. Recen
ad ancemen s in molecula biology and omics echnologies ha e led o he disco e y o no el bioma ke s ha can
de ec diseases a he molecula o cellula le el long be o e symp oms appea . These include gene ic, p o eomic,
me abolomic, epigene ic, and ci cula ing bioma ke s, which oge he o m he ounda ion o p ecision medicine14.
3.1. Gene ic Bioma ke s (DNA, RNA, MICRORNAS)
Gene ic bioma ke s in ol e al e a ions in DNA o RNA sequences ha a e associa ed wi h disease suscep ibili y, onse ,
o p og ession. Mu a ions, gene ampli ica ions, and ch omosomal ea angemen s se e as key indica o s in a ious
cance s25.Mic oRNAs (miRNAs)small non-coding RNAs egula e gene exp ession and a e eme ging as sensi i e
bioma ke s o ea ly de ec ion o cance s, ca dio ascula , and neu odegene a i e diseases. Fo example, miR-21 and
miR-155 a e ele a ed in se e al cance s, o e ing diagnos ic and p ognos ic alue15.
3.2. P o eomic Bioma ke s (P o ein Exp ession Pa e ns)
P o eomic bioma ke s e lec changes in p o ein abundance, s uc u e, o pos - ansla ional modi ica ion du ing
disease de elopmen . These bioma ke s a e c ucial because p o eins di ec ly media e physiological unc ions. Ad ances
in mass spec ome y and p o ein mic oa ays ha e enabled la ge-scale iden i ica ion o disease-speci ic p o ein
signa u es. Fo ins ance, ele a ed le els o p os a e-speci ic an igen (PSA) and CA-125 se e as indica o s o p os a e
and o a ian cance s, espec i ely16.
3.3. Me abolomic Bioma ke s (Me abolic Signa u es)
Me abolomic bioma ke s in ol e he analysis o small-molecule me aboli es ha e lec biochemical changes wi hin
cells and issues. Since me abolism is closely linked o cellula unc ion, me abolic al e a ions can indica e disease a
e y ea ly s ages. Techniques such as nuclea magne ic esonance (NMR) and mass spec ome y (MS) help iden i y
disease-speci ic me abolic signa u es, such as al e ed glucose o lipid p o iles in cance and diabe es17.
3.4. Epigene ic Bioma ke s (DNA Me hyla ion, His one Modi ica ions)
Epigene ic bioma ke s a e based on he i able changes in gene exp ession ha occu wi hou al e a ions in DNA
sequence. These include DNA me hyla ion and his one modi ica ion pa e ns, which can silence o ac i a e genes
in ol ed in umo igenesis. Abe an me hyla ion o umo supp esso genes like BRCA1 o p16INK4a has been
ecognized as an ea ly indica o o cance de elopmen 18.
3.5. Ci cula ing Tumo Cells and Exosomes
Ci cula ing umo cells (CTCs) and exosomes in blood a e minimally in asi e “liquid biopsy” ools ha p o ide eal-
ime in o ma ion abou umo biology. CTCs o e insigh in o me as asis, while exosomes—nano-sized esicles ca ying
DNA, RNA, and p o einsse e as ich sou ces o molecula bioma ke s o ea ly cance de ec ion. These ci cula ing
bioma ke s enable con inuous disease moni o ing and ea ly he apeu ic in e en ion wi hou he need o in asi e
p ocedu es19.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
368
Figu e 2No el bioma ke s in ea ly disease de ec ion
4. Applica ions o No el Bioma ke s in Speci ic Diseases
4.1. Cance
Cance emains a leading cause o mo bidi y and mo ali y wo ldwide, and ea ly de ec ion signi ican ly imp o es
he apeu ic success and su i al a es. The de elopmen o no el bioma ke s has ans o med oncology by enabling
non-in asi e, p ecise, and ea ly diagnosis.
Figu e 3 Applica ions o No el Bioma ke s in cance
Genomic bioma ke s such as BRCA1/2 mu a ions iden i y indi iduals wi h he edi a y b eas and o a ian cance isk,
allowing o p e en i e in e en ions. Ci cula ing umo DNA (c DNA) and cell- ee DNA (c DNA) ha e eme ged as
minimally in asi e liquid biopsy ools capable o de ec ing gene ic and epigene ic al e a ions associa ed wi h umo
p esence and e olu ion20.
Se um bioma ke s, including ca cinoemb yonic an igen (CEA), CA-125, and p os a e-speci ic an igen (PSA), a e
ou inely used in clinical diagnos ics, al hough hei speci ici y o ea ly de ec ion is limi ed. Recen ad ancemen s in
mic oRNA (miRNA) p o iling o example, up egula ion o miR-21, miR-155, and miR-210o e p omising a enues o
ea ly umo de ec ion, especially when in eg a ed wi h high- h oughpu sc eening pla o ms.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
369
The ad en o mul i-omics app oaches combining genomics, ansc ip omics, and p o eomics has u he enhanced
bioma ke accu acy, allowing o be e disease s a i ica ion, moni o ing he apeu ic esponses,andguiding p ecision
oncology21.
4.2. Ca dio ascula Diseases
Globally, ca dio ascula diseases (CVDs) con inue o be he leading cause o dea h.T adi ional diagnos ic ools such as
ECG and imaging de ec only o e s uc u al o unc ional changes, whe eas bioma ke s e eal ea ly
pa hophysiological al e a ions a he molecula le el.
Ca diac oponins (cTnI and cTnT) a e he gold s anda d bioma ke s o myoca dial in a c ion, indica ing
ca diomyocy e nec osis wi h high speci ici y and sensi i i y. B- ype na iu e ic pep ide (BNP) and N- e minal p oBNP
(NT-p oBNP) a e key bioma ke s o hea ailu e, co ela ing wi h en icula s ess and disease se e i y22.
Beyond hese, high-sensi i i y C- eac i e p o ein (hs-CRP) e lec s ascula in lamma ion and p edic s ca dio ascula
isk, while galec in-3, ST2, and g ow h di e en ia ion ac o -15 (GDF-15) a e eme ging ma ke s o myoca dial ib osis,
ca diac emodeling, and hea ailu e p ognosis.
No el omics-d i en bioma ke s, including speci ic lipidomic and me abolomic p o iles, a e being s udied o ea ly
de ec ion o a he oscle osis and subclinical CVD, pa ing he way o p edic i e ca diology23.
Figu e 4 Ca dio ascula diseses
4.3. Neu odegene a i e Diso de s
Neu odegene a i e diseases such as Alzheime ’s disease (AD), Pa kinson’s disease (PD), and amyo ophic la e al
scle osis (ALS) a e cha ac e ized by p og essi e neu onal damage, o en de ec ed only a e signi ican cogni i e o
mo o impai men .
Ce eb ospinal luid (CSF) bioma ke s including amyloid-β42 (Aβ42), o al au ( - au), and phospho yla ed au (p- au)
a e well-es ablished indica o s o AD pa hology, co ela ing wi h amyloid deposi ion and neu o ib illa y angles24.
Neu o ilamen ligh chain (NFL), measu able in bo h CSF and blood, is an eme ging bioma ke e lec ing axonal damage
ac oss mul iple neu odegene a i e diso de s. In PD, α-synuclein agg ega es, pa icula ly phospho yla ed o oligome ic
o ms, a e unde in es iga ion as diagnos ic and p og ession ma ke s.
Recen ad ancemen s in plasma-based bioma ke s and exosomal p o iling ha e enabled less in asi e de ec ion,
suppo ing ea ly diagnosis and longi udinal disease moni o ing.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
370
In eg a ion o hese bioma ke s wi h neu oimaging and gene ic es ing holds po en ial o p eclinical de ec ion and
pe sonalized he apeu ic s a egies25.
Figu e 5 Neu odegene a i e Diso de s
4.4. In ec ious Diseases
The global bu den o in ec ious diseases unde sco es he need o apid, accu a e, and ea ly diagnos ics. Bioma ke s
acili a e he dis inc ion be ween bac e ial and i al in ec ions, guide ea men selec ion, and moni o he apeu ic
esponse.
P ocalci onin (PCT) and C- eac i e p o ein (CRP) emain he mos widely used bioma ke s o bac e ial in ec ion and
sepsis, assis ing clinicians in an ibio ic s ewa dship.
In i al in ec ions, de ec ion o speci ic nucleic acids such as HIV RNA, HBV DNA, o HCV RNA se es as di ec molecula
bioma ke s o in ec ion s a us and i al load quan i ica ion.
Figu e 6 In ec ious Diseases
Du ing he COVID-19 pandemic, ma ke s like in e leukin-6 (IL-6), D-dime , C- eac i e p o ein, and e i in we e c i ical
in iden i ying se e e in lamma o y esponses and p edic ing clinical ou comes.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
371
Eme ging echnologies such as p o eomics, me abolomics, and hos - esponse signa u es a e unco e ing pa hogen-
speci ic bioma ke s ha could e olu ionize ea ly de ec ion and ou b eak con ol26.
5. Techniques o Bioma ke De ec ion
Bioma ke de ec ion echniques a e essen ial o iden i ying molecula signa u es ha indica e physiological o
pa hological condi ions. These me hods a e b oadly classi ied in o molecula , p o eomic, and me abolomic pla o ms.
5.1. Molecula Techniques
Molecula echniques a e p ima ily used o de ec ing gene exp ession, gene ic mu a ions, and nucleic acid
quan i ica ion. The mos commonly used molecula me hods include:
5.1.1. Polyme ase Chain Reac ion (PCR)
PCR and i s a ian s (RT-PCR, qPCR) ampli y speci ic DNA o RNA sequences, allowing o sensi i e and speci ic
de ec ion o gene ic ma ke s associa ed wi h diseases27.
5.1.2. Nex -Gene a ion Sequencing (NGS)
This high- h oughpu sequencing me hod enables comp ehensi e analysis o gene ic a ia ions, ansc ip omes, and
epigene ic changes, use ul in cance genomics and p ecision medicine.
5.1.3. Mic oa ays
DNA and RNA mic oa ays allow simul aneous analysis o housands o genes, acili a ing gene exp ession p o iling and
bioma ke disco e y in diseases such as cance and ca dio ascula diso de s28.
5.2. P o eomic and Me abolomic Pla o ms
P o eomic and me abolomic echniques iden i y and quan i y p o eins and me aboli es ha e lec he unc ional s a e
o biological sys ems.
5.2.1. Mass Spec ome y (MS)
A key analy ical ool in p o eomics and me abolomics, MS enables high- esolu ion de ec ion and quan i ica ion o
biomolecules. When combined wi h sepa a ion echniques such as liquid ch oma og aphy (LC-MS) o gas
ch oma og aphy (GC-MS), i p o ides insigh s in o p o ein modi ica ions, me abolic pa hways, and disease
mechanisms29.
5.2.2. Two-Dimensional Gel Elec opho esis (2D-GE)
Commonly used in p o eomic analysis, i sepa a es p o eins based on isoelec ic poin and molecula weigh be o e
iden i ica ion by MS.
Toge he , hese echniques con ibu e signi ican ly o p ecision diagnos ics, d ug de elopmen , and pe sonalized
medicine by p o iding a deepe unde s anding o molecula and biochemical al e a ions in disease s a es30.
5.3. Imaging-Based Bioma ke De ec ion
Imaging-based bioma ke de ec ion is a powe ul app oach used o isualize and quan i y biological p ocesses in li ing
o ganisms. I enables non-in asi e assessmen o molecula and cellula changes associa ed wi h disease onse ,
p og ession, and he apeu ic esponse. Bioma ke s de ec ed h ough imaging echniques p o ide c ucial insigh s o
ea ly diagnosis, pe sonalized medicine, and eal- ime moni o ing o ea men e icacy31.
This echnique combines molecula imaging echnologies wi h speci ic p obes o con as agen s ha a ge bioma ke s
such as p o eins, ecep o s, o me abolic pa hways. Common imaging modali ies include magne ic esonance imaging
(MRI), posi on emission omog aphy (PET), compu ed omog aphy (CT), single-pho on emission compu ed
omog aphy (SPECT), and op ical imaging. Each me hod p o ides dis inc in o ma ionPET and SPECT e eal me abolic
o unc ional ac i i y, while MRI and CT o e high- esolu ion ana omical de ails.
GSC Biological and Pha maceu ical Sciences, 2025, 33(01), 364–376
372
Imaging bioma ke s a e widely used in oncology, neu ology, and ca diology. Fo ins ance, luo odeoxyglucose (FDG) in
PET imaging helps de ec me abolic ac i i y in cance cells, while amyloid PET imaging assis s in diagnosing Alzheime ’s
disease. In ca dio ascula diseases, MRI can iden i y issue pe usion and iabili y, se ing as a eliable bioma ke o
ischemic damage. Op ical imaging using luo escen and bioluminescen p obes is also gaining a en ion o p eclinical
esea ch due o i s sensi i i y and sa e y32.
Recen ad ances ha e ocused on de eloping mul imodal imaging p obes, which in eg a e mul iple imaging capabili ies
(e.g., PET/MRI o CT/op ical), p o iding comp ehensi e s uc u al and unc ional da a. Nano echnology-based con as
agen s, such as quan um do s and gold nanopa icles, ha e u he enhanced signal sensi i i y and speci ici y. A i icial
in elligence and machine lea ning a e now being in eg a ed in o imaging analysis o au oma ically de ec and quan i y
bioma ke s om complex da ase s.
Despi e i s ad an ages, imaging-based bioma ke de ec ion aces challenges such as high cos , limi ed accessibili y, and
he need o s anda dized quan i ica ion me hods. Con inued esea ch aims o de elop sa e , mo e p ecise imaging
agen s and imp o e image p ocessing algo i hms o achie e be e clinical ansla ion33.
6. Clinical Signi icance and Challenges
Enzyme-based bioma ke de ec ion is a co ne s one o mode n diagnos ic science, allowing o he p ecise
iden i ica ion and quan i ica ion o biological molecules associa ed wi h diseases. Enzymes, due o hei high ca aly ic
e iciency and speci ici y, se e as biological ecogni ion elemen s ha can de ec minu e changes in bioma ke
concen a ion. Clinically, hese assays a e applied in diagnosing cance , ca dio ascula diso de s, diabe es, and
in ec ious diseases. Despi e hei diagnos ic alue, he ansi ion om esea ch o clinical applica ion aces se e al
challenges. Fac o s such as enzyme ins abili y, in e e ence om biological ma ices, and a ia ions in sample
p epa a ion can educe assay pe o mance. Fu he mo e, he lack o s anda diza ion among labo a o ies complica es
esul in e p e a ion. Ensu ing ep oducibili y and obus ness ac oss di e se popula ions and heal hca e se ings
emains an ongoing challenge. The e o e, con inued e o s in assay op imiza ion, alida ion, and in eg a ion wi h digi al
diagnos ic pla o ms a e c ucial o clinical success34.
6.1. Sensi i i y and Speci ici y Issues
The diagnos ic accu acy o enzyme-based assays is p ima ily de e mined by hei sensi i i y and speci ici y. Sensi i i y
ensu es ha e en ace le els o bioma ke s a e de ec ed, enabling ea ly disease diagnosis and moni o ing. Speci ici y,
on he o he hand, p e en s alse-posi i e ou comes by ensu ing ha only he a ge molecule eac s. Howe e ,
challenges such as enzyme deg ada ion, c oss- eac i i y wi h simila molecules, and a ia ions in assay calib a ion can
comp omise hese pa ame e s. Ad anced echniques like luo escence esonance ene gy ans e (FRET),
elec ochemical biosensing, and nanoma e ial-assis ed enzyme immobiliza ion a e being explo ed o enhance
sensi i i y and selec i i y. The combina ion o enzyme sys ems wi h mic o luidics and AI-d i en da a in e p e a ion has
also imp o ed diagnos ic p ecision35.
6.2. Cos and Accessibili y
One o he majo ba ie s o widesp ead adop ion o enzyme-based bioma ke de ec ion is i s cos . The expense o high-
pu i y eagen s, sophis ica ed analy ical ins umen s, and he equi emen o skilled ope a o s inc ease o e all
diagnos ic cos s. In low- and middle-income coun ies, his limi s ou ine clinical use. Recen esea ch is ocused on
de eloping po able, cos -e ec i e enzyme-based biosenso s using pape -based o wea able pla o ms, which can
p o ide apid and eliable esul s a he poin o ca e. Such inno a ions aim o b idge he gap be ween labo a o y
diagnos ics and ield-based applica ions, imp o ing heal hca e accessibili y globally36.
6.3. E hical and Regula o y Conside a ions
Implemen ing enzyme-based bioma ke assays in heal hca e equi es adhe ence o s ic e hical and egula o y
amewo ks. Pa ien sa e y, in o med consen , da a con iden iali y, and accu a e esul epo ing a e undamen al
e hical conce ns. Regula o y app o al om au ho i ies such as he U.S. FDA and he Eu opean Medicines Agency (EMA)
ensu es es quali y, eliabili y, and sa e y be o e clinical deploymen . Fu he mo e, equi able access o diagnos ic
echnologies mus be main ained o a oid dispa i ies in heal hca e. Con inuous pos -ma ke su eillance and
anspa en communica ion o diagnos ic ou comes s eng hen public us and uphold e hical s anda ds37.
